These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38191799)

  • 1. FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models.
    Galpin KJC; Rodriguez GM; Maranda V; Cook DP; Macdonald E; Murshed H; Zhao S; McCloskey CW; Chruscinski A; Levy GA; Ardolino M; Vanderhyden BC
    Sci Rep; 2024 Jan; 14(1):787. PubMed ID: 38191799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the Fibrinogen-Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13.
    Luft O; Khattar R; Farrokhi K; Ferri D; Yavorska N; Zhang J; Sadozai H; Adeyi O; Chruscinski A; Levy GA; Selzner N
    Immunology; 2018 Jul; 154(3):476-489. PubMed ID: 29341118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer.
    Zhu Y; Zhang L; Zha H; Yang F; Hu C; Chen L; Guo B; Zhu B
    Int J Biol Sci; 2017; 13(6):804-814. PubMed ID: 28656005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE.
    Khattar R; Luft O; Yavorska N; Shalev I; Phillips MJ; Adeyi O; Gao D; Bartczak A; Urbanellis P; Shyu W; Zhang J; Manuel J; Levy GA; Selzner N
    PLoS One; 2013; 8(10):e72309. PubMed ID: 24146739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression.
    Liu H; Shalev I; Manuel J; He W; Leung E; Crookshank J; Liu MF; Diao J; Cattral M; Clark DA; Isenman DE; Gorczynski RM; Grant DR; Zhang L; Phillips MJ; Cybulsky MI; Levy GA
    Eur J Immunol; 2008 Nov; 38(11):3114-26. PubMed ID: 18991288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice.
    Wang J; Vuitton DA; Müller N; Hemphill A; Spiliotis M; Blagosklonov O; Grandgirard D; Leib SL; Shalev I; Levy G; Lu X; Lin R; Wen H; Gottstein B
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003755. PubMed ID: 25955764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells.
    Wu L; Liu X; Lei J; Zhang N; Zhao H; Zhang J; Deng H; Li Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
    Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
    J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Regulatory T Cells (Treg) and the Treg Effector Molecule Fibrinogen-like Protein 2 in Alloimmunity and Autoimmunity.
    Chruscinski A; Sadozai H; Rojas-Luengas V; Bartczak A; Khattar R; Selzner N; Levy GA
    Rambam Maimonides Med J; 2015 Jul; 6(3):. PubMed ID: 26241231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated macrophage polarization promotes the progression of esophageal carcinoma.
    Yuan X; Li Y; Zhang AZ; Jiang CH; Li FP; Xie YF; Li JF; Liang WH; Zhang HJ; Liu CX; Pang LJ; Shen XH; Li F; Hu JM
    Aging (Albany NY); 2020 Dec; 13(2):2049-2072. PubMed ID: 33323552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
    Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis.
    Shalev I; Wong KM; Foerster K; Zhu Y; Chan C; Maknojia A; Zhang J; Ma XZ; Yang XC; Gao JF; Liu H; Selzner N; Clark DA; Adeyi O; Phillips MJ; Gorczynski RR; Grant D; McGilvray I; Levy G
    Hepatology; 2009 Feb; 49(2):387-97. PubMed ID: 19085958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors.
    Zhang S; Rao G; Heimberger A; Li S
    Cytokine Growth Factor Rev; 2023 Feb; 69():73-79. PubMed ID: 36085259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble Fgl2 restricts autoimmune hepatitis progression via suppressing Tc17 and conventional CD8+ T cell function.
    Ai G; Yan W; Yu H; Xiao F; Xi D; Ma K; Huang J; Luo X; Wan X; Ning Q
    J Gene Med; 2018 Jul; 20(7-8):e3023. PubMed ID: 29756667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regulatory T cell effector molecule fibrinogen-like protein 2 is necessary for the development of rapamycin-induced tolerance to fully MHC-mismatched murine cardiac allografts.
    Urbanellis P; Shyu W; Khattar R; Wang J; Zakharova A; He W; Sadozai H; Amir AZ; Shalev I; Phillips MJ; Adeyi O; Ross H; Grant D; Levy GA; Chruscinski A
    Immunology; 2015 Jan; 144(1):91-106. PubMed ID: 24990517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological functions and clinical implications of fibrinogen-like 2: A review.
    Yang G; Hooper WC
    World J Clin Infect Dis; 2013 Aug; 3(3):37-46. PubMed ID: 26161303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis.
    Shalev I; Liu H; Koscik C; Bartczak A; Javadi M; Wong KM; Maknojia A; He W; Liu MF; Diao J; Winter E; Manuel J; McCarthy D; Cattral M; Gommerman J; Clark DA; Phillips MJ; Gorczynski RR; Zhang L; Downey G; Grant D; Cybulsky MI; Levy G
    J Immunol; 2008 Jan; 180(1):249-60. PubMed ID: 18097026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation.
    Bartczak A; Chruscinski A; Mendicino M; Liu H; Zhang J; He W; Amir AZ; Nguyen A; Khattar R; Sadozai H; Lobe CG; Adeyi O; Phillips MJ; Zhang L; Gorczynski RM; Grant D; Levy GA
    Am J Transplant; 2016 Jun; 16(6):1739-50. PubMed ID: 26718313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.